The Glial Firestorm: Targeting Ferroptotic Microglia-Astrocyte Crosstalk in Intracerebral Hemorrhage
Related Experiment Video
Updated: Oct 31, 2026

A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia
Published on: November 14, 2020
Peixin Guo1, Honglin Chen1, Nan Li1
1The Fourth Department of Acupuncture and Moxibustion, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People's Republic of China.
Abstract:
Intracerebral hemorrhage (ICH) causes substantial mortality and disability, with secondary injury extending beyond the initial hematoma. This narrative review examines the working hypothesis that ferroptotic microglia amplify a neurotoxic astrocyte response after ICH. In the iron-rich hemorrhagic milieu, microglial iron loading and impaired antioxidant defenses favor lipid peroxidation, whereas inflammatory astrocyte states marked by LCN2, C3, and MMP3 contribute to barrier dysfunction and neuronal injury. Findings from ICH and related experimental models suggest that oxidized lipids, extracellular vesicles, and inflammatory mediators could connect these responses. Reactive astrocytes may then reinforce myeloid oxidative stress through altered iron handling, glutamate clearance, and complement signaling. Ferroptosis must be considered alongside apoptosis, necroptosis, and pyroptosis, and resident microglia share erythrophagocytic and iron-handling functions with infiltrating monocytes/macrophages. These overlapping processes limit the attribution of mixed myeloid signals to a single lineage or death pathway. The proposed bidirectional circuit remains a framework for testing rather than an established sequence in ICH. Therapeutic interception could combine early control of iron-dependent lipid injury with later astrocyte modulation through STAT3 or PPAR-γ, provided that beneficial hematoma clearance is preserved. High-resolution spatiotemporal mapping, lineage-resolved experiments, and sex-specific analyses are needed to identify the relevant cells and treatment windows. Targeting this glial interaction may complement neuroprotection, but its therapeutic value requires direct experimental and clinical validation.
